RT Journal Article SR Electronic T1 European Respiratory Society statement on long COVID follow-up JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 2102174 DO 10.1183/13993003.02174-2021 VO 60 IS 2 A1 Antoniou, Katerina M. A1 Vasarmidi, Eirini A1 Russell, Anne-Marie A1 Andrejak, Claire A1 Crestani, Bruno A1 Delcroix, Marion A1 Dinh-Xuan, Anh Tuan A1 Poletti, Venerino A1 Sverzellati, Nicola A1 Vitacca, Michele A1 Witzenrath, Martin A1 Tonia, Thomy A1 Spanevello, Antonio YR 2022 UL https://publications.ersnet.org//content/60/2/2102174.abstract AB Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient's quality of life (QoL). A European Respiratory Society (ERS) Task Force convened and prioritised eight clinical questions. A targeted search of the literature defined the timeline of “long COVID” as 1–6 months post-infection and identified clinical evidence in the follow-up of patients. Studies meeting the inclusion criteria report an association of characteristics of acute infection with persistent symptoms, thromboembolic events in the follow-up period, and evaluations of pulmonary physiology and imaging. Importantly, this statement reviews QoL consequences, symptom burden, disability and home care follow-up. Overall, the evidence for follow-up care for patients with long COVID is limited.Follow-up care of patients infected with SARS-CoV-2 is crucial and may improve their quality of life. More evidence and research is emerging to understand the causes, mechanisms and risks of long COVID consequences. https://bit.ly/3J1WMWy